Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | THRB | P10828 | 1/20 | 0.75 |
| ▸ | MTOR | P42345 | 1/20 | 0.75 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.75 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.75 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.60 |
| ▸ | ST6GAL1 | P15907 | 5/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9010747 | 0.90 | LMNA (0.72) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5491562 | 0.90 | LMNA (0.75) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4946508 | 0.90 | LMNA (0.75) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14178411 | 0.89 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2811458 | 0.89 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL13524621 | 0.89 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL383499 | 0.89 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL17304691 | 0.89 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18231346 | 0.89 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL15338532 | 0.89 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024144420-A1 | USE OF 5'-О-(3-PHENYLPROPIONYL)-N4-HYDROXYCYTIDINE TO INHIBIT INFLUENZA VIRUS REPLICATION IN VITRO AND IN VIVO | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | 2024-07-04 | — | — | WO | claimed |
| WO-2024129551-A1 | SOLID DOSAGE FORM OF A SMALL MOLECULE ANTIVIRAL AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4380578-A1 | METHOD OF TREATING VETERINARY VIRAL DISEASES | Intervet International B.V. (NL) | 2024-06-12 | — | — | EP | claimed |
| EP-4319763-A2 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | Emory University (US) | 2024-02-14 | — | — | EP | claimed |
| EP-4319764-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | claimed |
| EP-4319762-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | claimed |
| US-20240041828-A1 | Combination Therapeutics Comprising Nrf2 Agonists and Antivirals for Treating Viral Infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-08 | — | — | US | claimed |
| US-20230193231-A1 | ENGINEERED GENE-EDITING PROTEINS | FACTOR BIOSCIENCE INC. | 2023-06-22 | — | — | US | claimed |
| EP-4149252-A2 | ENGINEERED GENE-EDITING PROTEINS | Factor Bioscience Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| EP-4142744-A1 | MESENCHYMAL STEM CELL THERAPIES | Factor Bioscience Inc. (US) | 2023-03-08 | — | — | EP | claimed |
| CN-115768474-A | Methods for treating COVID-19 related disorders | 里格尔药品股份有限公司 | 2023-03-07 | — | — | CN | claimed |
| WO-2023012329-A1 | METHOD OF TREATING VETERINARY VIRAL DISEASES | INTERVET INTERNATIONAL B.V. (NL) | 2023-02-09 | — | — | WO | claimed |
| WO-2022217155-A2 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2022212914-A1 | METHODS OF TREATING VIRAL DISEASES | AMPIO PHARMACEUTICALS, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2021231549-A2 | ENGINEERED GENE-EDITING PROTEINS | FACTOR BIOSCIENCE INC. (US) | 2021-11-18 | — | — | WO | claimed |
| WO-2021222389-A1 | MESENCHYMAL STEM CELL THERAPIES | FACTOR BIOSCIENCE INC. (US) | 2021-11-04 | — | — | WO | claimed |
| EP-1725266-A4 | POTENT MUCOSAL IMMUNE RESPONSE INDUCED BY MODIFIED IMMUNOMODULATORY OLIGONUCLEOTIDES | HYBRIDON INC (US) | 2008-05-07 | — | — | EP | claimed |
| EP-1725266-A2 | POTENT MUCOSAL IMMUNE RESPONSE INDUCED BY MODIFIED IMMUNOMODULATORY OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005081847-A2 | POTENT MUCOSAL IMMUNE RESPONSE INDUCED BY MODIFIED IMMUNOMODULATORY OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| WO-2003035836-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON INC. (US) | 2003-05-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041828-A1 | Combination Therapeutics Comprising Nrf2 Agonists and Antivirals for Treating Viral Infections | KEAP1, HMOX1, NFE2L2 | LMNA 2186/4885THRB 2846/4885MTOR 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.